Coverage of our peer-reviewed research in the healthcare and mainstream press.
Healthcare organizations have been slow offer greater price transparency to patients, according to a recent article on PatientEngagementHIT.com. It also noted that “price transparency is not common and not all patients want or need it to be,” citing the findings from a study featured in the June 2017 issue of The American Journal of Managed Care® (AJMC®). The interviews described in the study, “Patients’ Views on Price Shopping and Price Transparency,” revealed that patients rarely used a price transparency tool offered by their employer to shop around for care.
A news release from the Massachusetts Institute of Technology announced the results of a health app that encourages adherence in patients with diabetes, and referenced an AJMC® study to demonstrate how improving adherence can have major financial implications. “Association Among Change in Medical Costs, Level of Comorbidity, and Change in Adherence Behavior,” which was published in the August 2016 issue of AJMC®, found that patients with diabetes saved $5341 annually after becoming adherent.
A HealthPayerIntelligence.com article discussed how payers can support accountable care organizations (ACOs) in taking on 2-sided risk. It quoted a letter to the editor in the December 2016 issue of AJMC® to support its argument that insurers can “nudge ACOs along” by providing resources while not imposing burdens in the form of reporting requirements. In the letter, “Patient-Centered Care: Turning the Rhetoric Into Reality,” the authors wrote, “The first step is for government and private payers to stop constantly piling new requirements upon the old.”
Global Trends in Ovarian Cancer Incidence Highlight Regional, Histological Variations
January 7th 2025Between 1988 and 2017, there were significant global variations and trends in ovarian cancer incidence and its subtypes, influenced by genetic, reproductive, and socioeconomic factors.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Decisions and Precision in Value-Based Cancer Care
January 7th 2025An Institute for Value-Based Medicine regional event in Houston, Texas, covered inconsistencies with the integration of precision medicine in oncology practices, the evolution of treatment for multiple myeloma, and more.
Read More